Clinical trials: Oral Cancers
Gynaecomastia, Prostate Cancer
Casodex - Nolvadex Combination
This study looks at the relationship in the dose of nolvadex and the incidence of gynaecomastia and also Prostate Specific Antigen (PSA) inhibition when co-administered with Casodex.
- Trial name
- NCT00637871
- Testing
- Casodex, Tamoxifen
- Sponsor
- AstraZeneca
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Colorectal Cancer
DJ-927 as Second-Line Therapy in Treating Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma
RATIONALE: Drugs used in chemotherapy, such as DJ-927, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00080834
- Testing
- DJ-927
- Where
- 2 sites in United States
- Sponsor
- Daiichi Sankyo
Cancer
BCX-1777 in Treating Patients With Refractory Cancer
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: Phase I trial to study the effectiveness of BCX-1777 in treating patients who have refractory cancer.
- Trial name
- NCT00073944
- Testing
- forodesine hydrochloride
- Where
- United States
- Sponsor
- BioCryst Pharmaceuticals
Cancer, Solid Tumor
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
A Phase 1B/2A study will be conducted to establish safety and dose level of AMXT 1501 dicaprate in combination with IV DFMO, in cancer patients.
- Conditions
- Cancer, Solid Tumor, Solid Carcinoma, Advanced Cancer
- Trial name
- NCT05500508
- Testing
- AMXT1501, DFMO
- Where
- 7 sites in United States, Australia
- Volunteers
- 15 people
- Sponsor
- Aminex Therapeutics, Inc.
Malignant Melanoma, Neoplasms
A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)
This open-label, multi-center, three-period, one-sequence study will investigate the effect of rifampin on the PK of vemurafenib in participants with unresectable BRAFV600-mutation positive metastatic melanoma or other malignant…
- Trial name
- NCT01765543
- Testing
- Rifampin, Vemurafenib
- Where
- 15 sites in United States, Brazil and 3 more
- Volunteers
- 27 people
- Sponsor
- Hoffmann-La Roche
Solid Tumours
Study to Assess the Blood Levels and Safety of Olaparib in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment
This is a 2-part study in patients with advanced solid tumours. Part A will investigate the PK of olaparib in patients with mild or moderate hepatic impairment compared to patients with normal hepatic function; Part B will allow…
- Trial name
- NCT01894243
- Testing
- Olaparib tablet dosing
- Where
- 12 sites in Czechia, France and 3 more
- Volunteers
- 31 people
- Sponsor
- AstraZeneca
Advanced Solid Tumors, Breast Cancer Recurrent
First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers
The goal of this study is to identify a safe and tolerated dose of the orally administered DHX9 inhibitor ATX-559. In addition, this study will evaluate the pharmacokinetics, pharmacodynamics and preliminary antitumor activity of…
- Conditions
- Advanced Solid Tumors, Breast Cancer Recurrent, Colorectal Cancer Metastatic, Colon Cancer
- Trial name
- NCT06625515
- Testing
- ATX-559
- Where
- 5 sites in United States
- Volunteers
- 17 people
- Sponsor
- Accent Therapeutics
Solid Tumours
Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors
To determined what dose of topotecan can be safely given with daily pazopanib.
- Trial name
- NCT00732420
- Testing
- topotecan, pazopanib
- Where
- 3 sites in United States, Netherlands
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Tumors
A Study of Oral Suberoylanilide Hydroxamic Acid (Vorinostat) in Patients With Solid Tumors (0683-048)
This is a clinical study to evaluate the safety and pharmacokinetics of an overseas determined maximum tolerated dose (MTD) of MK-0683 (vorinostat) in a Japanese patient population with solid tumors.
- Trial name
- NCT00373490
- Testing
- Vorinostat
- Volunteers
- 16 people
- Sponsor
- Merck Sharp & Dohme LLC
NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic
First in Human Multicenter Open Name Dose-increase, Consolidation Method to Study Safety Drug-level in Blood & Drug Metabolism Clinical Activity of Oral JBI-778 in Lung Cancer Patients With, Without Brain Metastasis IDH Mutated WHO Grade 3,4 Recurrent Glioma, Salivary Glands Tumor
This is a phase 1, multicentre, first-in-human, open-label, dose-escalation/consolidation study to investigate the safety, pharmacokinetics, pharmacodynamics, and clinical activity of orally administered JBI-778 in EGFR mutated…
- Conditions
- NSCLC Patients With EGFR Activating Mutation, Adenoid Cystic Carcinoma Metastatic, Adenoid Cystic Carcinoma of the Head and Neck
- Trial name
- NCT07755397
- Testing
- JBI-778
- Where
- 6 sites in India
- Volunteers
- 30 people
- Sponsor
- Jubilant Therapeutics India Limited
Acute Myeloid Leukemia (AML)
A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy
This study will be conducted in two parts. Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA).
- Trial name
- VIALE-M (NCT04102020)
- Testing
- Venetoclax, Azacitidine
- Where
- 156 sites in United States, Australia and 17 more
- Volunteers
- 112 people
- Sponsor
- AbbVie
Oral Mucositis
Observational Study of Anti-Cancer Therapy Induced Oral Mucositis in Korean Cancer Patients
to survey oral mucositis after chemotherapy and Concurrent chemoradiotherapy in Korean cancer patients
- Trial name
- NCT00549952
- Testing
- no intervention study
- Where
- South Korea
- Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
Diffuse Large B-Cell Lymphoma
A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets Compared to Intravenously (IV) Infused Rituximab Plus IV Infused Gemcitabine and IV Infused Oxaliplatin in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
B-cell Lymphoma is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections).
- Trial name
- EPCORE DLBCL-4 (NCT06508658)
- Testing
- Epcoritamab, Rituximab, Lenalidomide
- Where
- 176 sites in United States, Argentina and 26 more
- Volunteers
- 379 people
- Sponsor
- Genmab
Prostate Cancer, Endometriosis
A Phase 1 Study to Evaluate the Effects of Fluconazole and Atorvastatin on the Pharmacokinetics of TAK-385 in Healthy Subjects
This is a nonrandomized, open-label, fixed-sequence, 2-arm study designed to assess the effect of multiple doses of fluconazole or atorvastatin on the single-dose pharmacokinetics of TAK-385 in healthy adult subjects.
- Trial name
- NCT02093390
- Testing
- TAK-385, Fluconazole, Atorvastatin
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Millennium Pharmaceuticals, Inc.
Non Small Cell Lung Cancer, Pancreatic Cancer
Study of Covalent Menin Inhibitor BMF-219 in Adult Patients With KRAS Driven Non-Small Cell Lung Cancer, Pancreatic Cancer, and Colorectal Cancer
A Phase 1/1b dose finding study to determine the OBD(s) and RP2D(s) of BMF-219, a covalent menin inhibitor small molecule, in subjects with KRAS mutated unresectable, locally advanced, or metastatic NSCLC (Cohort 1), PDAC (Cohort…
- Conditions
- Non Small Cell Lung Cancer, Pancreatic Cancer, Colorectal Cancer, NSCLC
- Trial name
- NCT05631574
- Testing
- BMF-219
- Where
- 23 sites in United States, South Korea
- Volunteers
- 13 people
- Sponsor
- Biomea Fusion Inc.
Prostate Neoplasms
An Observational Study of Continuous Oral Dosing of Abiraterone Acetate in Castration-Resistant Prostate Cancer Patients Evaluating Androgens and Steroid Metabolites in Bone Marrow Plasma
The purpose of this study is to investigate the effect of abiraterone acetate on levels of androgens and steroid metabolites in bone marrow plasma of patients with metastatic castration-resistant prostate cancer (CRPC).
- Trial name
- NCT00544440
- Testing
- Abiraterone acetate, Prednisone
- Where
- United States
- Volunteers
- 57 people
- Sponsor
- Janssen Research & Development, LLC
Hepatocellular Carcinoma
A Phase 1-2 Study of CF102 in Patients With Advanced Hepatocellular Carcinoma
This trial will test the safety and efficacy of CF102 in patients with advanced liver cancer. Successive groups of patients will be given higher doses of CF102 by mouth on a twice-daily basis.
- Trial name
- NCT00790218
- Testing
- CF102
- Where
- Israel
- Volunteers
- 19 people
- Sponsor
- Can-Fite BioPharma
Sarcoma
A Study of RO5045337 in Combination With Doxorubicin in Patients With Soft Tissue Sarcoma
This multicenter, open-label, Phase 1b study will evaluate the safety, pharmacokinetics and efficacy of RO5045337 in combination with doxorubicin in patients with soft tissue sarcoma.
- Trial name
- NCT01605526
- Testing
- RO5045337, doxorubicin
- Where
- 9 sites in United States, France
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Advanced Solid Tumors
This Is The First Study Using Escalating Doses Of PF-03758309, An Oral Compound, In Patients With Advanced Solid Tumors
This is the first study using PF-03758309, an oral compound, in patients with advanced solid tumors. In this study different doses of PF-03758309 will be administered to different groups of patients.
- Trial name
- NCT00932126
- Testing
- PF-03758309
- Where
- 3 sites in United States, Australia
- Volunteers
- 35 people
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.